22Rv1, AR, AR splice variants, ARLPC, ARPC, ARPC PDX models, ARPC tumors, Androgen, Androgen receptor, C4-2B, CH5183284, CRPC, CRPC cell lines, Cell lines, DNPC, E2F, E2F and MYC target genes, ENZA, FGF, FGFR, FGFR1, FGFR1-4, FGFRi, G2M checkpoint genes, LuCaP PDX models, LuCaP PDX tumor, LuCaP PDX tumor cells, LuCaP patient-derived xenograft (PDX) models, MYC, PDX models, RNA, SCNPC, SCNPC models, SCNPC tumors, VCaP, castration-resistant prostate cancer, castration-resistant prostate cancer (CRPC) tumors, double-negative prostate cancer, enzalutamide, erdafitinib, fibroblast growth factor, fibroblast growth factor receptor, metastatic CRPC, patient, prostate cancer, small cell or neuroendocrine prostate cancer, tumor